Infantile haemangioma (IH) is the most frequent tumour of infancy. Although it is benign and self-limiting, severe complications can arise due to localisation and fast tumour growth. Also, IHs leave scars after regression in more than half of the cases. Management and therapy of IH have changed greatly after 2008. This update provides an overview of the older therapy options before 2008, which mainly consisted of the administration of corticosteroids, and discusses the modern management with new therapy options such as β-blockers (both systemically and topically). Conclusion: β-blockers are promising and are currently preferred above corticosteroids, but β-blockers still do not give a definitive treatment.

Beta-blockers, Corticosteroids, Infantile haemangioma, Propranolol, Scoring system, Therapy, Timolol
dx.doi.org/10.1007/s00431-014-2404-5, hdl.handle.net/1765/88446
European Journal of Pediatrics
Department of Pediatric Surgery

Janmohamed, S.R, Madern, G.C, de Laat, P.C.J, & Oranje, A.P. (2014). Educational paper: therapy of infantile haemangioma-history and current state (part II). European Journal of Pediatrics. doi:10.1007/s00431-014-2404-5